Antihistamine drug terfenadine suppressed the cycle progression of gastric cancer cells by targeting PI3K/AKT/mTOR signaling

Background: Gastric cancer (GC) remains a leading cause of cancer-related mortality worldwide, highlighting the urgent need for effective and accessible therapies. Drug repurposing offers a cost-effective strategy to identify novel candidates from approved drugs. Terfenadine, a classical antihistamine with an established safety profile, has demonstrated antitumor activity in various malignancies; however, its efficacy and mechanism in GC have not been systematically explored. This study investigates the therapeutic potential of terfenadine in GC and elucidates its underlying molecular mechanisms. Methods: efficacy was validated in a patient-derived xenograft (PDX) model. Results: < 0.001). Conclusion: efficacy in a clinically relevant PDX model. These findings support the repurposing of terfenadine as a promising therapeutic agent for GC.